Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEZLFT)

• Drug Name: Camsirubicin Drug Info
• Synonyms: UNII-VI79RD8VNN; VI79RD8VNN; 236095-26-4; (8R,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8H)-one; 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)-

Indication

Disease Entry	ICD 11	Status	REF
Soft tissue sarcoma	2B57	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 135446069
  CAS Number: CAS 236095-26-4
  TTD Drug ID: DMEZLFT

Molecule-Related Drug Atlas

Drug(s) Targeting DNA topoisomerase II alpha (TOP2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PK1	DMKEV7N	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Annamycin	DMDHJNV	Acute myeloid leukaemia	2A60	Phase 1/2	[4]
NK314	DMY729C	T-cell leukaemia	2A90	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II alpha (TOP2A)	TTCGY2K	TOP2A_HUMAN	Inhibitor	[2]

References

• [1] Clinical pipeline report, company report or official report of Monopar Therapeutics.
• [2] Clinical pipeline report, company report or official report of Monopar Therapeutics.
• [3] Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36.
• [4] Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8.
• [5] NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20.